{"id":6670,"date":"2011-03-01T17:16:08","date_gmt":"2011-03-01T22:16:08","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=6670"},"modified":"2011-07-19T17:44:31","modified_gmt":"2011-07-19T21:44:31","slug":"cv-patients-without-hypertension-benefit-from-antihypertensive-therapy","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/03\/01\/cv-patients-without-hypertension-benefit-from-antihypertensive-therapy\/","title":{"rendered":"CV Patients Without Hypertension Benefit From Antihypertensive Therapy"},"content":{"rendered":"<p>A new study suggests that patients with CV disease who do not have hypertension may nevertheless benefit from antihypertensive therapy. In <a href=\"http:\/\/jama.ama-assn.org\/content\/305\/9\/913.short\">a study published in\u00a0<em>JAMA<\/em><\/a>, Angela Thompson and colleagues performed a meta-analysis of 25 trials including 64,162 patients with CV disease or a risk factor equivalent and without hypertension. Compared to controls, patients who received antihypertensive therapy had<\/p>\n<ul>\n<li>a 23% reduction in risk of stroke,<\/li>\n<li>a 29% reduction in risk of CHF events,<\/li>\n<li>a 15% reduction in risk of a combination of CVD events,<\/li>\n<li>and a 13% reduction in risk of all-cause mortality.<\/li>\n<\/ul>\n<p>In <a href=\"http:\/\/jama.ama-assn.org\/content\/305\/9\/940\">an accompanying editorial<\/a>, Hector Ventura and Carl Lavie write that &#8220;the clinical importance of this study is clear:\u00a0pharmacological intervention in patients with CVD and blood pressure levels less than 140\/90 mm Hg is associated with a decreased risk of cardiovascular morbidity and mortality.&#8221; However, they point out that since &#8220;many patients could potentially begin taking medications at young ages and for many years to prevent cardiovascular events, even modest costs and adverse effects need to be considered.&#8221;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A new study suggests that patients with CV disease who do not have hypertension may nevertheless benefit from antihypertensive therapy. In a study published in\u00a0JAMA, Angela Thompson and colleagues performed a meta-analysis of 25 trials including 64,162 patients with CV disease or a risk factor equivalent and without hypertension. Compared to controls, patients who received [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[718,454],"class_list":["post-6670","post","type-post","status-publish","format-standard","hentry","category-prevention","tag-antihypertensive-therapy","tag-hypertension"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/6670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=6670"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/6670\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=6670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=6670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=6670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}